These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 29992431)

  • 1. Influence of riociguat treatment on pulmonary arterial hypertension : A meta-analysis of randomized controlled trials.
    Zhao R; Jiang Y
    Herz; 2019 Nov; 44(7):637-643. PubMed ID: 29992431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study).
    Marra AM; Halank M; Benjamin N; Bossone E; Cittadini A; Eichstaedt CA; Egenlauf B; Harutyunova S; Fischer C; Gall H; Ghofrani HA; Hoeper MM; Lange TJ; Olsson KM; Klose H; Grünig E
    Respir Res; 2018 Dec; 19(1):258. PubMed ID: 30567595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study.
    Nathan SD; Behr J; Collard HR; Cottin V; Hoeper MM; Martinez FJ; Corte TJ; Keogh AM; Leuchte H; Mogulkoc N; Ulrich S; Wuyts WA; Yao Z; Boateng F; Wells AU
    Lancet Respir Med; 2019 Sep; 7(9):780-790. PubMed ID: 31416769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Riociguat for patients with chronic thromboembolic pulmonary hypertension: Usefulness of transitioning from phosphodiesterase type 5 inhibitor.
    Yamamoto K; Tanabe N; Suda R; Sasaki A; Matsumura A; Ema R; Kasai H; Kato F; Sekine A; Nishimura R; Jujo T; Sugiura T; Shigeta A; Sakao S; Tatsumi K
    Respir Investig; 2017 Jul; 55(4):270-275. PubMed ID: 28705306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Balloon pulmonary angioplasty vs riociguat in patients with inoperable chronic thromboembolic pulmonary hypertension: A systematic review and meta-analysis.
    Wang W; Wen L; Song Z; Shi W; Wang K; Huang W
    Clin Cardiol; 2019 Aug; 42(8):741-752. PubMed ID: 31188483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension.
    Ghofrani HA; D'Armini AM; Grimminger F; Hoeper MM; Jansa P; Kim NH; Mayer E; Simonneau G; Wilkins MR; Fritsch A; Neuser D; Weimann G; Wang C;
    N Engl J Med; 2013 Jul; 369(4):319-29. PubMed ID: 23883377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Change of right heart size and function by long-term therapy with riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Marra AM; Egenlauf B; Ehlken N; Fischer C; Eichstaedt C; Nagel C; Bossone E; Cittadini A; Halank M; Gall H; Olsson KM; Lange TJ; Grünig E
    Int J Cardiol; 2015 Sep; 195():19-26. PubMed ID: 26011408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Riociguat for the treatment of pulmonary arterial hypertension.
    Ghofrani HA; Galiè N; Grimminger F; Grünig E; Humbert M; Jing ZC; Keogh AM; Langleben D; Kilama MO; Fritsch A; Neuser D; Rubin LJ;
    N Engl J Med; 2013 Jul; 369(4):330-40. PubMed ID: 23883378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Individual dose adjustment of riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Hill NS; Rahaghi FF; Sood N; Frey R; Ghofrani HA
    Respir Med; 2017 Aug; 129():124-129. PubMed ID: 28732819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial.
    Ghofrani HA; Grimminger F; Grünig E; Huang Y; Jansa P; Jing ZC; Kilpatrick D; Langleben D; Rosenkranz S; Menezes F; Fritsch A; Nikkho S; Humbert M
    Lancet Respir Med; 2016 May; 4(5):361-71. PubMed ID: 27067479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial Riociguat Monotherapy and Transition from Sildenafil to Riociguat in Patients with Idiopathic Pulmonary Arterial Hypertension: Influence on Right Heart Remodeling and Right Ventricular-Pulmonary Arterial Coupling.
    Taran IN; Belevskaya AA; Saidova MA; Martynyuk TV; Chazova IE
    Lung; 2018 Dec; 196(6):745-753. PubMed ID: 30182153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study.
    Bonderman D; Ghio S; Felix SB; Ghofrani HA; Michelakis E; Mitrovic V; Oudiz RJ; Boateng F; Scalise AV; Roessig L; Semigran MJ;
    Circulation; 2013 Jul; 128(5):502-11. PubMed ID: 23775260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A focus on riociguat in the treatment of pulmonary arterial hypertension.
    Toxvig AK; Wehland M; Grimm D; Infanger M; Krüger M
    Basic Clin Pharmacol Toxicol; 2019 Sep; 125(3):202-214. PubMed ID: 31206240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Riociguat for the treatment of pulmonary hypertension.
    Meis T; Behr J
    Expert Opin Pharmacother; 2014 Nov; 15(16):2419-27. PubMed ID: 25260791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential treatment with sildenafil and riociguat in patients with persistent or inoperable chronic thromboembolic pulmonary hypertension improves functional class and pulmonary hemodynamics.
    Darocha S; Banaszkiewicz M; Pietrasik A; Piłka M; Florczyk M; Wieteska M; Dobosiewicz A; Szmit S; Torbicki A; Kurzyna M
    Int J Cardiol; 2018 Oct; 269():283-288. PubMed ID: 30017517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Riociguat for pulmonary arterial hypertension associated with congenital heart disease.
    Rosenkranz S; Ghofrani HA; Beghetti M; Ivy D; Frey R; Fritsch A; Weimann G; Saleh S; Apitz C
    Heart; 2015 Nov; 101(22):1792-9. PubMed ID: 26135803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of hemodynamic parameters in treatment-naïve and pre-treated patients with pulmonary arterial hypertension in the randomized phase III PATENT-1 study.
    Galiè N; Grimminger F; Grünig E; Hoeper MM; Humbert M; Jing ZC; Keogh AM; Langleben D; Rubin LJ; Fritsch A; Davie N; Ghofrani HA
    J Heart Lung Transplant; 2017 May; 36(5):509-519. PubMed ID: 28190787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Bishop BM
    Am J Health Syst Pharm; 2014 Nov; 71(21):1839-44. PubMed ID: 25320133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Riociguat: Mode of Action and Clinical Development in Pulmonary Hypertension.
    Ghofrani HA; Humbert M; Langleben D; Schermuly R; Stasch JP; Wilkins MR; Klinger JR
    Chest; 2017 Feb; 151(2):468-480. PubMed ID: 27263466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Riociguat: a novel new drug for treatment of pulmonary hypertension.
    Makowski CT; Rissmiller RW; Bullington WM
    Pharmacotherapy; 2015 May; 35(5):502-19. PubMed ID: 26011143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.